Sarepta Therapeutics Inc. | $SRPT Stock | CEO Surprises Investors With Strong Exondys 51 Sales

By |January 11th, 2017|

Sarepta Therapeutics Inc. (NASDAQ: SRPT)
Sarepta Therapeutics News
On Tuesday Sarepta Therapeutics ($SRPT) released surprising  data on its recently approved Duchenne muscular dystrophy drug, Exondys 51. The CEO Ed Kay stated that sales have surpassed expectations and have now reached $5.4 million in the fourth quarter while expectations were at $4.9 million. Stock prices soared over […]